Eli Lilly and Company (LLY) Análisis de acciones

Descripción de la empresa

Eli Lilly and Company operates as a comprehensive pharmaceutical enterprise focused on the discovery, development, manufacturing, and marketing of human pharmaceutical products across the United States, Europe, China, Japan, and international markets. The company functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - General industry, positioning it as a key player in the provision of essential therapeutic solutions for diverse medical conditions. As of the latest reporting period, the entity holds a substantial market capitalization of $786.04B and generates annual revenue of $65.18B while employing a workforce of 50000 individuals. These financial magnitudes and operational scale indicate that Eli Lilly commands a dominant position within the global pharmaceutical landscape, reflecting its capability to invest heavily in research and development while maintaining extensive distribution networks. The massive valuation underscores the market's confidence in the company's ability to deliver consistent value through its broad portfolio of cardiometabolic health products and other therapeutic areas.

Salud financiera

The company reported a trailing twelve-month revenue of $65.18B, with corresponding net income of $20.64B and EBITDA reaching $31.69B, illustrating a robust top-line performance supported by significant operating earnings. The substantial gap between the $65.18B revenue and the $20.64B net income reveals a highly efficient cost structure where operating expenses and taxes consume approximately 68.3% of total sales, yet still leave a highly profitable remainder. Eli Lilly generated free cash flow of $1.95B, a metric that highlights the company's ability to convert earnings into actual cash available for strategic reinvestment, debt reduction, or capital allocation initiatives. While the firm maintains a cash balance of $7.27B against total debt of $43.87B, the balance sheet reflects a leveraged structure rather than a purely conservative one, as indicated by the debt-to-equity ratio of 165.31. Despite the high leverage, the current ratio stands at 1.58, which indicates that the company possesses sufficient short-term assets to cover its current liabilities with a comfortable margin of safety. Furthermore, the return on equity of 101.2% and return on assets of 19.4% demonstrate exceptional management effectiveness in utilizing shareholder capital and assets to generate superior returns relative to industry standards.

Evaluación de valoración

Valuation metrics for Eli Lilly show a trailing P/E ratio of 38.32 compared to a forward P/E of 20.86, implying that the market expects a significant acceleration in earnings growth that would justify the current high multiple. The price-to-book ratio of 29.62 indicates that the stock trades at a substantial premium over its book value, suggesting that investors are pricing in intangible assets such as intellectual property, brand strength, and future growth potential rather than just tangible equity. Alternative valuation metrics including a price-to-sales ratio of 12.06 and an EV/EBITDA of 25.91 further suggest that the market is willing to pay a premium for the company's high margins and growth prospects relative to peers. In terms of trading range, the stock has reached a 52-week high of $1133.95 and a 52-week low of $623.78, providing a wide band of volatility over the past year. The beta value of 0.43 indicates that the stock exhibits significantly lower price volatility relative to the broader market, making it a less sensitive asset to general market fluctuations.

Growth & Income

Eli Lilly is currently experiencing strong momentum with revenue growth of 42.6% and earnings growth of 51.4% year over year, indicating that earnings are expanding at a faster rate than revenue, which typically implies improving operational leverage or margin expansion. As a company with a dividend yield of 0.7% and a payout ratio of 26.1%, the entity demonstrates a sustainable dividend policy where the payout is well-covered by earnings, allowing for stability even during periods of earnings fluctuation. The relatively low payout ratio leaves ample room for the company to retain earnings for research and development or share buybacks while maintaining a consistent income stream for shareholders. Overall, the growth and income profile presents a compounder characteristic where high earnings growth supports a modest but reliable dividend, balancing capital appreciation potential with income generation.